Tissue Kallikrein supplementation in ischemic phase protects the neurovascular unit and attenuates reperfusion-induced injury in ischemic stroke

• Published in: Pharmacological research Vol. 209; p. 107435
• Main Authors: Ran, Xiao, Xu, Tingting, Ruan, Hang, Wang, Xiaochuan, Zhang, Qin
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01.11.2024; Elsevier
• Subjects: Aged; Animals; Endothelial cells; Female; Humans; Ischemia-Reperfusion; Ischemic Stroke; Ischemic Stroke - drug therapy; Ischemic Stroke - metabolism; Ischemic Stroke - prevention & control; Kallikrein-kinin system; Male; Middle Aged; Neuroprotective Agents - administration & dosage; Neuroprotective Agents - pharmacology; Neuroprotective Agents - therapeutic use; Receptor, Bradykinin B1 - metabolism; Receptor, Bradykinin B2 - metabolism; Reperfusion Injury - drug therapy; Reperfusion Injury - metabolism; Reperfusion Injury - prevention & control; Retrospective Studies; Signal Transduction - drug effects; Tissue kallikrein; Tissue Kallikreins; Ischemia-Reperfusion; Tissue kallikrein; Kallikrein-kinin system; Endothelial cells; Ischemic Stroke
• ISSN: 1043-6618; 1096-1186; 1096-1186
• DOI: 10.1016/j.phrs.2024.107435

Tissue kallikrein (TK) has emerged as a potential neuroprotective agent in ischemic stroke (IS), yet the optimal timing and mechanisms of TK therapy remain unclear. Here, we established a causal link between lower baseline TK levels and an increased risk of stroke through a retrospective, multicente...